Phase 3 N=640 Chloroquine Alone or in Combination for Malaria in Children in Malawi
Plasmodium Falciparum Infection
Primary: Number of Clinical Malaria Episodes Per Year of Follow-up — 0.61; 0.68; 0.64; 0.59 Episodes per PYAR — p=0.8097
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=60 FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali
Malaria · Plasmodium Falciparum Malaria
Primary: Safety and Reactogenicity (SAEs and AEs) — 45; 53; 22; 37 Number of events
Phase 2 N=252 Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...
Malaria
Primary: Number of Participants With Positive Sensitive Blood Smear (sBS) — 0; 0 Participants
Phase 2 N=6 Anti-malaria MAb in Malian Children
Plasmodium Falciparum Infection · Malaria
Primary: Participants With Local Adverse Events (AEs) - Year One — 3; 1; 0; 0 Participants
Phase 2 N=12 Anti-malaria MAb in Kenyan Children
Plasmodium Falciparum Infection · Malaria
Primary: Number of Participants With Local Adverse Events (AEs) — 0; 1; 1; 1 Participants
Phase 2 N=1,301 Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali
Malaria
Primary: Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 — 15; 14; 15; 15 Participants
N/A N=1,000 Validation of RealAmp Method for the Diagnosis of Malaria in Endemic Areas of Brazil
Malaria Diagnosis
Primary: Malaria Diagnosis Using RealAmp and Microscopy. — 42; 153; 0; 1 Participants
Phase 2 N=100 Methylene Blue Against Falciparum Malaria in Burkina Faso
Malaria, Falciparum
Primary: Change in Haemoglobin Compared to the Baseline — 0.18; 0.54 g/dl
Phase 2 N=400 Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali
Plasmodium Falciparum Malaria
Primary: Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the First Vaccination — 0; 5; 0; 12 Participants
Phase 2 N=400 Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine
Malaria, Falciparum
Primary: Subjects Time to First Clinical Episode of P Falciparum Malaria During the Efficacy Follow-up Period Adjusted for Time at Risk - Intent to Treat (ITT) Population — 107…
Phase 2 N=620 Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy
Plasmodium Falciparum
Primary: Time to First PCR-detectable Malaria Infection During the Active Detection of Infection (ADI) Phase in Groups 1 and 4 — 1.01; 1.49 Events per person year at risk — p=0.009
Phase 2 N=308 A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV
HIV · Pregnancy Malaria · Sexually Transmitted Infection
Primary: Plasmodium Falciparum Peripheral Parasitemia — 8; 7 Participants
N/A N=2,421 Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
Malaria
Primary: Number of Subjects With Plasmodium Falciparum (P. Falciparum) Parasitaemia (PFP), by Study Center — 235; 153; 167; 141 Participants
Phase 2 N=110 A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria
Falciparum Malaria
Primary: Percentage of Participants With Parasite Clearance at Day 28 — 97.20 percentage of participants
Phase 2 N=70 Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria
Malaria · Severe Malaria
Primary: Parasite Clearance Half-life — 1.733; 1.973 Hours — p=>0.05
Phase 1 N=210 Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali
Malaria
Primary: Number of Participants With Local and Systemic Adverse Events in Year One — 39; 27; 19; 11 Participants
Phase 1 N=2 Blood-Stage Plasmodium Vivax Cell Bank
Malaria
Primary: P. Vivax Blood Collection — 2 Participants
Phase 1 N=88 First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants
Healthy
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation of Study Treatment — 13; 6; 5; 3…
Phase 2 N=193 Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults
Malaria Vaccine
Primary: Number of Participants Who Experience a Serious Adverse Events (SAEs) 29 Days After the Last Vaccination — 1; 0; 0; 1 Participants
Phase 1 N=40 Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali
Malaria
Primary: Number of Participants With Solicited Adverse Events by Immunization and Type — 8; 18; 4; 13 Participants
Phase 4 N=14,075 A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)
Malaria
Primary: Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Infants and Children (<5 Years) in Post Community…
Phase 2 N=66 Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)
Malaria
Primary: Cure Rates of AQ-13 and Coartem for Uncomplicated Plasmodium Falciparum Malaria in Adult Malian Males. — 28; 31 Participants
Phase 3 N=151 Superiority of ArTiMist Versus Quinine in Children With Severe Malaria
Plasmodium Falciparum Malaria
Primary: Parasitological Success (MITT) — 66; 28; 4; 43 participants — p=<0.005
Phase 1 N=22 DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria
Plasmodium Falciparum, Malaria
Primary: Infection Rate — 5; 6; 3; 0 Participants
Phase 1 N=100 Phase I Pediatric FMP2.1/AS02A Trial in Mali
Plasmodium Falciparum Malaria
Primary: Occurrence of Solicited Systemic Symptoms During a 7-day Surveillance Period (Systematically Collected) Following Vaccinations at Days 0, 30, and 60. — 0; 0; 0; 0…
Phase 2 N=6 Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali
Plasmodium Falciparum Infection · Malaria
Primary: Participants With Local Adverse Events (AEs) — 1; 0; 0; 2 Participants
Phase 2 N=340 Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
Malaria · Malaria Vaccines
Primary: Concentrations of Antibodies Against Hepatitis B (Anti-HB) — 13.0; 14.3; 16.9; 111.8 milli-international unit per milliliter
Phase 3 N=1,703 Chloroquine for Malaria in Pregnancy
Malaria
Primary: Incidence of Placental Malaria Infection Based on Histology — 11.58; 15.42; 15.42 percentage of pregnancies — p=0.2441
N/A N=96 Chloroquine and Post Malaria Anaemia Study
Malaria Anaemia
Primary: Changes in Haemoglobin Concentration From Day 3 Post Treatment of Malaria Episode to Day 90 in the Weekly Chloroquine and Placebo Arms — 93.4; 93.7 g/L
Phase 1 N=2 Dose Escalation PfSPZ-CVac
Malaria
Primary: Number of Participants With P.Falciparum Blood Stage Infection — 0; 0; 0; 0 Participants